Skip to content
Screener

Delcath Systems DCTH HEPZATO KIT — Product revenue

Other product segments

CHEMOSAT
$1.97M+19.1%

Similar metrics at other companies

GigaCloud Technology logo
GCTProduct revenues — Revenue
$290.82M+28.9%
Itron logo
ITRIProduct revenues — Revenue
$453.46M-12.3%
Corcept Therapeutics logo
CORTHypercortisolism Products — Product revenue, net
$208.58M+7.3%
Xerox Holdings Corporation logo
XRXIT products — Total Revenues
$140M-8.5%
Syndax Pharmaceuticals logo
SNDXNet Product Revenues — Revenue
$31.21M+1,526%
Quanterix Corporation logo
QTRXProduct revenue — Total revenues
$23.48M+39.5%

Other financials

Income statement

See full
Revenue$29.1M+20.6%
Gross profit$26.1M+25.5%
Operating income$2.4M-7.5%
Net income$2.7M-1.1%
EPS (diluted)$0.070.0%

Balance sheet

See full
Cash & equivalents$47.5M+38.0%
Total debt$2.5M+148%
Total equity$121.1M+15.4%
Total assets$137.0M+17.2%

Cash flow

See full
Operating cash flow$5.7M-21.7%
CapEx$503.0K+26.4%
Free cash flow$5.2M-24.5%

Valuation

See full
Market cap$524.3M+57.3%
Enterprise value$479.26M+59.6%
P/E102.3×—
P/S5.5×+0.7×

Profitability

See full
Gross margin87.1%+1.2pp
Operating margin-118.1%-56.8pp
Net margin1.5%+0.8pp
FCF margin18.3%+12.8pp

Returns & leverage

See full
Return on equity1.9%+1.0pp
Debt / equity0×0.0×
Current ratio9.8×-1.0×

Where this comes from

Reported directly by Delcath Systems in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Delcath Systems’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 9:09 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053956
(In thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
CHEMOSAT$1,972$1,656$3,719$3,417
HEPZATO KIT27,16122,50050,40840,523
Total revenue$29,133$24,156$54,127$43,940

Item 1. Financial Statements

FAQ

What is Delcath Systems's HEPZATO KIT — product revenue?
Delcath Systems (DCTH) reported HEPZATO KIT — product revenue of $27.16M in Q2 2026.
How has Delcath Systems's HEPZATO KIT — product revenue changed year-over-year?
Delcath Systems's HEPZATO KIT — product revenue increased by 20.7% year-over-year, from $22.5M to $27.16M.
What does HEPZATO KIT — product revenue mean?
This metric measures the total gross sales generated from the commercialization of a specific product or service line. It reflects the market adoption, pricing power, and commercial success of the offering within its target therapeutic area. Tracking this revenue is essential for evaluating the growth trajectory and financial contribution of a specific business segment.

Ask your AI about Delcath Systems's hepzato kit — product revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude